🔗 Share this article WHO Raises Warning Over Acute Lack of Weight-Loss Jabs Fewer than a tenth of people who could benefit from obesity jabs like Wegovy have access to them, states the World Health Organization as it issues its initial recommendations on the therapies. Considering over a billion people worldwide now living with obesity, it is advocating for broader and more equitable access to this class of drugs. According to forecasts, over two billion will be obese by 2030 if no action is taken. "Our new guidelines affirms that obesity is a chronic disease that can be managed with holistic and lifelong support," said its chief Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and supply-chain constraints are major obstacles to broad access to the treatments that can aid individuals in losing significant weight, says the body. GLP-1 Therapy Supply Crisis Despite the current most optimistic case, the production of such drugs could only cover around 100 million people – under 10% of the global need, per the health organization. The recommendation urges countries and companies to widen access, through strategies including patent sharing. A patent on semaglutide – the primary component of Novo Nordisk's Wegovy – is set to lapse in multiple nations in 2026. How Obesity Injections Work These medications replicate a biological compound to slow digestion, curb appetite and boost satiety so users consume fewer calories. People usually begin shedding pounds within a few weeks of commencing the regular doses. Research suggests patients may regain a significant portion within a year of discontinuing the drug, as their normal hunger return. Being above a healthy weight elevates your risk for experiencing medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies. Obesity impacts individuals in every country and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.
Fewer than a tenth of people who could benefit from obesity jabs like Wegovy have access to them, states the World Health Organization as it issues its initial recommendations on the therapies. Considering over a billion people worldwide now living with obesity, it is advocating for broader and more equitable access to this class of drugs. According to forecasts, over two billion will be obese by 2030 if no action is taken. "Our new guidelines affirms that obesity is a chronic disease that can be managed with holistic and lifelong support," said its chief Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and supply-chain constraints are major obstacles to broad access to the treatments that can aid individuals in losing significant weight, says the body. GLP-1 Therapy Supply Crisis Despite the current most optimistic case, the production of such drugs could only cover around 100 million people – under 10% of the global need, per the health organization. The recommendation urges countries and companies to widen access, through strategies including patent sharing. A patent on semaglutide – the primary component of Novo Nordisk's Wegovy – is set to lapse in multiple nations in 2026. How Obesity Injections Work These medications replicate a biological compound to slow digestion, curb appetite and boost satiety so users consume fewer calories. People usually begin shedding pounds within a few weeks of commencing the regular doses. Research suggests patients may regain a significant portion within a year of discontinuing the drug, as their normal hunger return. Being above a healthy weight elevates your risk for experiencing medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies. Obesity impacts individuals in every country and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.